Covered recipient · General Payments record
WILLIAM DAVID KOLTUN
Allopathic & Osteopathic Physicians Obstetrics & Gynecology Gynecology
General Payments · PY2018
$10,758.35
- Reported across 18 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2018 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Travel and Lodging | $4,849.37 | 10 |
| Consulting Fee | $4,712.50 | 1 |
| Food and Beverage | $1,196.48 | 7 |
By paying entity
PY2018 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lupin Inc. | $7,606.00 | 9 |
| Eli Lilly and Company | $1,631.04 | 5 |
| Novo Nordisk AS | $1,521.31 | 4 |
By program year
All program years on this page · sorted by year
| Program year | Amount | Records |
|---|---|---|
| PY2018 | $10,758.35 | 18 |
Payment records · PY2018 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Eli Lilly and Company | $677.32 | 01/10/2018 | Travel and Lodging | Undisputed | 01/23/2026 | 559925755 | CMS |
| Eli Lilly and Company | $318.50 | 01/13/2018 | Food and Beverage | Undisputed | 01/23/2026 | 559925761 | CMS |
| Eli Lilly and Company | $182.00 | 01/13/2018 | Travel and Lodging | Undisputed | 01/23/2026 | 559925767 | CMS |
| Eli Lilly and Company | $414.40 | 01/13/2018 | Travel and Lodging | Undisputed | 01/23/2026 | 559925773 | CMS |
| Eli Lilly and Company | $38.82 | 01/29/2018 | Food and Beverage | Undisputed | 01/23/2026 | 559925779 | CMS |
| Lupin Inc. | $1,929.99 | 04/04/2018 | Travel and Lodging | Undisputed | 01/23/2026 | 605064311 | CMS |
| Lupin Inc. | $216.66 | 04/21/2018 | Travel and Lodging | Undisputed | 01/23/2026 | 605064313 | CMS |
| Lupin Inc. | $376.29 | 04/21/2018 | Travel and Lodging | Undisputed | 01/23/2026 | 605064315 | CMS |
| Lupin Inc. | $4,712.50 | 05/01/2018 | Consulting Fee | Undisputed | 01/23/2026 | 605064317 | CMS |
| Lupin Inc. | $31.70 | 05/01/2018 | Travel and Lodging | Undisputed | 01/23/2026 | 605064319 | CMS |
| Lupin Inc. | $73.10 | 07/02/2018 | Food and Beverage | Undisputed | 01/23/2026 | 605064321 | CMS |
| Lupin Inc. | $138.90 | 07/02/2018 | Food and Beverage | Undisputed | 01/23/2026 | 605064323 | CMS |
| Lupin Inc. | $68.76 | 07/02/2018 | Food and Beverage | Undisputed | 01/23/2026 | 605064325 | CMS |
| Lupin Inc. | $58.10 | 07/02/2018 | Food and Beverage | Undisputed | 01/23/2026 | 605064327 | CMS |
| Novo Nordisk AS | $136.87 | 04/11/2018 | Travel and Lodging | Undisputed | 01/23/2026 | 603538465 | CMS |
| Novo Nordisk AS | $268.96 | 04/11/2018 | Travel and Lodging | Undisputed | 01/23/2026 | 603538527 | CMS |
| Novo Nordisk AS | $500.30 | 04/11/2018 | Food and Beverage | Undisputed | 01/23/2026 | 603538557 | CMS |
| Novo Nordisk AS | $615.18 | 04/11/2018 | Travel and Lodging | Undisputed | 01/23/2026 | 603538649 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018
- Source files
- Dataset page · Bulk file · PY2018
- Generated from
- OP_DTL_GNRL_PGYR2018_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.